BioCentury
ARTICLE | Clinical News

Forty Seven reports Phase Ib data for Hu5F9-G4 in B cell NHL

June 1, 2018 6:24 PM UTC

Forty Seven Inc. (Menlo Park, Calif.) reported data from 22 evaluable patients with relapsed or refractory B cell non-Hodgkin's lymphoma (NHL) in the Phase Ib portion of a Phase Ib/II trial showing that Hu5F9-G4 plus Rituxan rituximab led to an objective response rate (ORR) of 50%, including seven complete responses. The data were released in an abstract ahead of the American Society of Clinical Oncology (ASCO) meeting in Chicago.

In 15 patients with diffuse large B cell lymphoma (DLBCL), Hu5F9-G4 plus Rituxan led to an ORR of 40%, including four complete responses. In seven patients with follicular lymphoma, the combination led to an ORR of 71%, including three complete responses...

BCIQ Target Profiles

CD47